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Mild renal ischemia activates primed neutrophils to cause acute
renal failure
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University of Colorado Health Sciences Center, Webb Waring Lung Institute, Denver General Hospital, Denver, Colorado, USA
Mild renal ischemia activates primed neutrophils to cause acute renal
failure. The role of neutrophils (PMN) in acute renal failure (ARF) is
controversial. Although the development of acute renal failure (ARF)
frequently occurs in situations where there is partial activation of PMN
(primed PMN) and mild renal isehemia, the interaction between primed
PMN and ischemic organs has not been studied in any biological
system. To define the interaction between primed PMN and mild renal
ischemia, kidneys were made ischemic for 10 minutes in situ and
reperfused by the isolated kidney technique with untreated PMN or
PMN primed with low concentrations of lipopolysaccharide (LPS) or
phorbol mynstate acetate (PMA). We found that primed PMN had no
effect on control (non-ischemic) kidneys and that untreated PMN did
not cause injury to kidneys previously subjected to mild ischemia.
However, addition of primed PMN to mildly ischemic kidneys caused
severe injury. To determine the nature of renal injury, ischemic kidneys
were reperfused with primed PMN and catalase (CAT) or the elastase
inhibitor, Eglin C. In ischemic kidneys reperfused with LPS-pnmed
PMN, Eglin C (but not CAT) was partially protective while in ischemic
kidneys reperfused with PMA-primed PMN, CAT (but not Eglin C) was
partially protective. Reperfusion with both CAT and Eglin C com-
pletely prevented the damaging effects of either LPS- or PMA-primed
PMN. In conclusion, addition of primed but not untreated PMN causes
ARF in mildly ischemic kidneys by PMN oxidant- and/or protease-
mediated mechanisms. This synergism could account for the high
frequency of ARF in conditions associated with prerenal azotemia and
primed PMN.
Acute renal failure (ARF) commonly occurs in conjunction
with gram negative sepsis, Adult Respiratory Distress Syn-
drome and multiple organ failure syndrome [l—4]. The etiology
of renal failure in these diseases is unknown but is surely
complex and multifactorial. A number of factors could contrib-
ute to loss of renal function in these situations. The possibilities
include hypotension and renal ischemia, antibiotic therapy (for
example aminoglycosides), eicosanoids [5], platelet activating
factor [6], cytokines [7] and, possibly, products of activated
neutrophils (PMN) such as oxygen radicals and proteases [8].
Studies evaluating the contribution of PMN to ARF have
yielded confusing results. Whereas some investigators have
reported that PMN worsen ischemic renal injury [9, 10], others
have not been able to identify a role of PMN in ARF [11, 12].
Careful evaluation reveals that the experimental design of these
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latter studies has often included the use of untreated or quies-
cent PMN or fully activated PMN. However, most clinical
conditions associated with ARF are likely to be associated with
"primed" or partially activated PMN rather than with resting or
fully activated PMN [13, 14]. Primed PMN are raised to
heightened states of responsiveness by exposure to low con-
centrations of stimuli that do not fully activate PMN to release
effectors such as oxidants or proteases [15, 16]. The effect of
primed PMN on renal function or on other organs has not been
reported. Moreover, in clinical conditions associated with
ARF, prerenal azotemia is noted or the kidney is likely to be
marginally ischemic rather than being completely normal. It
appears, therefore, that to understand the interaction between
PMN and ARF a most relevant approach would be an interme-
diate one—testing the effects of primed PMN on kidneys
subjected to minimal ischemic stress. This approach has not
been investigated previously and is the subject of the present
paper.
Our hypothesis was that normal kidneys are resistant to
attack by primed PMN and that mildly ischemic kidneys are
resistant to untreated PMN. However, minimal renal ischemia
predisposes to ARF by activating primed PMN which, depend-
ing on the nature of the priming agents, release oxidants and/or
proteases which injure kidneys. To determine the interaction
between primed PMN and partially ischemic kidneys, we used
the isolated perfused kidney. This simplified in vitro prepara-
tion was optimal because renal ischemia could be studied
without the confounding effects of changes in systemic hemo-
dynamics or in renal nerve function. Furthermore, the specific
effects of primed PMN on kidney function could be determined
in the absence of other confounding cellular elements and
circulating factors such as cytokines or vasoactive hormones
which are present during ARF in vivo.
Methods
Sources of reagents
The following reagents were used in this study: albumin
(fraction V-Cohn bovine, Intergen Co., Purchase, New York,
USA); hydroxyl ['4C} methyl inulin (Amersham, Arlington
Heights, Illinois, USA); phorbol myristate acetate (PMA) and
catalase (CAT) (bovine liver, 2,000 U/mg protein; Sigma Chem-
ical, St. Louis, Missouri, USA); lipopolysaccharide (LPS, #201
Escherichia coli 0111: B4, List Biological Laboratory, Inc.,
Campbell, California, USA); and Eglin C (Ciba-Geigy, Switzer-
land) [17, 18].
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Perfusion of isolated rat kidneys
Perfusion of the isolated rat kidney was conducted according
to Nishiitsutsuji-Uwo, Ross and Krebs [191 as modified by
Little and Cohen [20] and previously described in our labora-
tory [211. Briefly, after the right renal artery was cannulated,
the kidney was transferred to a perfusion chamber and perfused
using a pulsatile pump at a constant mean arterial pressure
(distal to the tip of the cannula) of 100 mm Hg. Following a 15
minute equilibration period, three urine collections and perfu-
sion samples were obtained at 15 minute intervals. Perfusion
samples were placed in a test tube for subsequent determina-
tions of sodium and ['4C] inulin. Each perfusion lasted for 60
minutes. Urine and perfusate samples were stored at —20°C
within 60 minutes of collection. For each perfusion, 150 ml of a
Krebs-Ringer bicarbonate solution was used that contained
urea, (hydroxyl [14C] methyl) inulin, and albumin. The final
composition of the perfusion medium (in m unless otherwise
noted) was 140 Na, 5.0 K, 1.2 ionized Ca, 1 Mg, 105 Cl, 25
bicarbonate, 1 sulfate, 1 phosphate, 7 urea, 70 mglml albumin,
5 glucose, and 1 mJIlOO ml perfusate of Aminosyn 8.5% (Abbott
Laboratories, North Chicago, Illinois, USA).
Measurement of renal injury
Measurements of giomerular filtration rate (GFR), tubular
sodium reabsorption (TNa), and perfusion flow rate (PFR) were
used to assess renal injury. Urinary clearances of ['4C] inulin
and sodium were calculated from their respective urine and
plasma concentration ratios. Sodium was measured with an IL
343 flamephotometer (Instrumentation Laboratory, Lexington,
Massachusetts, USA). Radioactivity of ['4C] inulin was
counted in a Packard Tricarb model 460 liquid scintillation
counter (Packard Instruments, Laguna Hills, California, USA).
Preparation of neutrophils
Neutrophils were purified from human blood anticoagulated
with sodium citrate (0.38%). Cells were separated by sedimen-
tation and centrifugation and then were resuspended in platelet-
poor plasma, diluted 1:4 with 6% dextran (Pharmacia Fine
Chemicals, Piscataway, New Jersey, USA) in saline. Erythro-
cytes were separated from leukocytes by sedimentation. Leu-
kocyte-rich supernatant was aspirated, underlaid with Ficoll-
Hypaque (Pharmacia Fine Chemicals, Piscataway, New Jersey,
USA), and centrifuged at 275 g to separate monocytes and
neutrophils. Sedimented neutrophils were resuspended in
Hank's buffered salt solution (HBSS) before injection into
perfusates. Final preparations contained 94 to 96% neutrophils
and 4 to 6% monocytes.
Preparation of phorbol myristate acetate (PMA)
PMA (12-0-tetradecanoyl-phorbol- 13-acetate) was dissolved
in dimethylsulfoxide at 1 mg/mi and divided into 200 g aliquots
that were frozen at —70°C. Just before use, aliquots were
thawed and diluted to 200 jtg/ml in normal saline.
Our investigations consisted of four experimental protocols:
Protocol 1. Protocol 1 was designed to determine the effects
of quiescent (untreated), primed (treated with low concentra-
tions of LPS or PMA) and activated (treated with high concen-
trations of LPS or PMA) PMN on isolated kidney function.
Isolated kidneys were perfused with PMN (3 x i05 cells/mi)
with LPS (10 /Lg/mi; N = 5), LPS (1 /Lg/ml, N = 5), PMA (1
nglml, N = 5), PMA (0.1 ng/ml, N = 6) or no additions (N = 6).
PMN, LPS and PMA were added to the perfusate at time 0 of
perfusion. In preliminary studies we determined that at these
concentrations, LPS or PMA had no effect on isolated kidney
function (PFR, GFR, TNa) in the absence of PMN.
Protocol 2. Protocol 2 was designed to determine the effects
of the duration of renal ischemia on recovery of renal function
during reperfusion. For these studies, kidneys were made
ischemic in situ by placing a non-traumatic clip on the renal
artery for 10 minutes (N = 6), 20 minutes (N = 5) or 30 minutes(N = 5) as previously described [221. Following ischemia,
kidneys were reperfused by the isolated kidney technique. For
reperfusion, a canula was placed in the proximal renal artery
then the clip was removed and the canula further inserted. This
procedure required less than five seconds and reperfusion time
was measured from the time of removal of the clip.
Protocol 3. Protocol 3 was designed to determine the inter-
action between mild renal isehemia and PMN. Kidneys were
made ischemic for 10 minutes in situ and reperfused by the
isolated kidney technique with PMN (3 x i0 cells/mi) and LPS
(1 tg/mi, N = 6), or PMA (0.1 ng/ml, N = 6) or no additions (N
= 10). PMN, LPS and PMA were added to the perfusate at time
0 of reperfusion.
Protocol 4. Protocol 4 was designed to determine the role of
02 metabolites and neutrophil elastase on the recovery of renal
function in kidneys made ischemic for 10 minutes and reper-
fused with primed PMN. For these studies the H202 scavenger,
CAT, and a non-oxidizable neutrophil elastase inhibitor, Eglin
C [17, 181, were utilized. In earlier studies we found that Eglin
C prevented elastase but not oxidant mediated kidney injury
[81. Two studies were performed. In the first, kidneys were
made ischemic for 10 minutes in situ and reperfused with PMN
and LPS (1 jsg/ml) and CAT (200 U/mi, N = 5), Eglin C (2 tiM,
N = 6), CAT and Eglin C (N = 6) or no additions (N = 5). In
the second, ischemic kidneys were reperfused with PMN and
PMA (0.1 ng/ml) with (N = 5) CAT (N = 6), Eglin C (N = 5),
CAT and Eglin C (N 6) or no additions (N 5).
Statistical analyses
Statistical analyses were performed using one-way analysis
of variance in conjunction with the Duncan's test for compari-
son of multiple means. A P value of <0.05 was considered
significant. Data were expressed as means SEM.
Results
Figure 1 shows the effect of addition of PMN and LPS on the
function of non-ischemic isolated perfused kidneys. Addition of
PMN or LPS alone did not alter GFR or TNa during the 60
minutes of perfusion (data not shown). However, addition of
both PMN and LPS caused LPS-concentration dependent de-
creases in renal function. Perfusion with higher concentrations
of LPS (10 pg/mi) and PMN caused time-dependent progressive
decreases in GFR and TNa (such as, to 50% and 83% of control
values after 60 mm of perfusion) while lower concentrations of
LPS (1 g/m1) and PMN did not decrease renal function.
Figure 2 reveals the effects of addition of PMA and PMN on
the function of non-ischemic isolated perfused kidneys. The
results with PMA were similar to results in kidneys perfused
with LPS. In kidneys exposed to higher concentrations of PMA
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(1 ng!ml), there were decreases in GFR and TNa (such as, to
40% and 75% of control values by 60 mm of perfusion). In
contrast, kidneys perfused with lower concentrations of PMA
(0.1 nglml) and PMN did not have decreases in GFR or TNa
compared to control kidneys. Thus, when stimulated by high
concentrations of LPS or PMA, PMN caused profound renal
injury to non-ischemic kidneys while non-ischemic kidneys did
not develop injury when perfused with PMN and lower concen-
trations of LPS or PMA [8, 9].
Figure 3 demonstrates the effect of increases in the duration
of renal ischemia in situ on recovery of function in isolated
perfused kidneys. No functional recovery in GFR or TNa
occurred during reperfusion following ischemia for 30 minutes.
Some functional recovery occurred in kidneys subjected to 20
minutes of ischemia and then 60 minutes of reperfusion but
GFR and TNa were still reduced to less than 40% and 90%,
respectively, of non-ischemic values. In contrast to longer
durations of ischemia, functional recovery was complete after
60 minutes of reperfusion in kidneys previously exposed to
ischemia for 10 minutes.
Figure 4 demonstrates the effects of 10 minutes of renal
ischemia in vivo followed by reperfusion with untreated or low
concentration LPS-treated PMN (that is, LPS-primed PMN) on
recovery of renal function. Addition of untreated PMN alone
did not alter recovery of renal function following 10 minutes of
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Fig. 1. Effect of addition of neutrophils
(PMN) with lipopolysaccharide (LPS) on the
45 60 function of non-ischemic isolated perfused
kidneys. Grey area denotes mean value SEM
(N = 10) for kidneys perfused without
additions. P < 0.01 vs. no additions.
MA(1ng/ml)
Fig. 2. Effect of addition of PMN with
phorbol myristate acetate (PMA) on the
45 60 function of non-ischemic isolated perfused
kidneys. Grey area denotes mean value SEM
Perfusion time (N = 10) for kidneys perfused without
minutes additions. P < 0.01 vs. no additions.
ischemia. After 60 minutes of reperfusion, GFR and TNa had
recovered to non-ischemic values. Compared to reperfusion of
ischemic kidneys with untreated PMN, reperfusion of ischemic
kidneys with LPS-primed PMN prevented recovery of renal
function. In preliminary studies, we determined that these
concentrations of LPS alone did not alter the course of recovery
from 10 minutes of ischemia in isolated perfused kidneys.
Figure 4 shows that after 60 minutes of reperfusion, GFR and
TNfl were reduced to 234 34 pi/min/g and 84 2% in kidneys
perfused with PMN and LPS compared to 531 25 1.d/minlgm
and 94 1% in kidneys reperfused with untreated PMN.
Figure 5 reveals the effects of reperfusion with low concen-
tration PMA-primed PMN on the function of kidneys subjected
to 10 minutes of ischemia. The results with PMA-primed PMN
are similar to those in kidneys reperfused with LPS-pnmed
PMN. Compared to reperfusion of ischemic kidneys with
untreated PMN, reperfusion with PMN exposed to low concen-
trations of PMA resulted in abnormal recovery. After 60
minutes of reperfusion GFR and TNa were reduced to 244 25
.d/min/gm and 85 1% in kidneys reperfused with untreated
PMN. The data from Figures 4 and 5 demonstrate that the
damaging effects of primed PMN on ischemic kidneys is more
than the effects of either ischemia or primed PMN alone. There
appears to be a synergy between ischemia and primed PMN on
renal injury.
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Fig. 4. Effect of addition of PMN alone or
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45 60 function after 10 minutes of ischemia in situ.
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Fig. 5. Effect of addition of PMN alone or
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<0.01 vs. non-ischemic kidneys.
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To determine if hydrogen peroxide or elastase from PMN
contributed to renal dysfunction in ischemic kidneys, CAT or
the non-oxidizable neutrophil elastase inhibitor Eglin C were
added to the perfusate along with PMN and LPS. Figure 6
indicates that the addition of Eglin C increased GFR and TNa
compared to no additions; however, after 60 minutes of reper-
fusion, renal function was less than non-ischemic kidneys. By
comparison, addition of CAT did not improve recovery of renal
function. Nonetheless, when kidneys were reperfused with
PMN and LPS along with both CAT and Eglin C, GFR and TNa
measurements were comparable to non-ischemic kidneys.
Figure 7 demonstrates the effect of addition of CAT and/or
Eglin C on ischemic kidneys exposed to PMN and PMA during
reperfusion. In contrast to PMN and LPS, addition of Eglin C
appeared to be without effect while addition of CAT increased
GFR and TNa to values which exceeded values in kidneys
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perfused with PMN and PMA but which were less than those of
non-ischemic kidneys. Furthermore, reperfusion with addition
of both CAT and Eglin C yielded values of GFR and TNa which
at 60 minutes of reperfusion, were comparable to non-ischemic
kidneys.
Discussion
In many clinical conditions associated with ARF, such as
gram negative sepsis, Adult Respiratory Distress Syndrome, or
multiple organ failure, PMN are neither inactivated nor fully
activated. Rather, PMN circulate in a primed state [13, 14]. The
effect of primed PMN on kidney or other organ function has not
been evaluated in either normal or ischemic organs. Our data
indicate that primed PMN do not injure non-ischemic kidneys
but damage mildly ischemic kidneys.
Prior studies on the interaction between PMN and kidneys
have yielded apparently conflicting results. First, activated
PMN can cause renal injury. Several groups have demonstrated
that activated PMN injure non-ischemic kidneys. Shah and his
associates demonstrated that PMN activated with PMA caused
degradation of human glomerular basement membranes [23].
Yoshioka and Ichikawa showed that PMN/PMA infused di-
rectly into rat renal arteries decreased GFR [241, and we found
that PMA activated PMN decreased GFR and TNa in non-
ischemic isolated perfused kidneys [9]. However, the impact of
untreated PMN on kidney function is less clear. Untreated
PMN do not alter non-ischemic kidney function, but cause
additional damage to kidneys previously made ischemic for 20
minutes [91. Moreover, Hellberg and Kallskog have reported
that untreated PMN contribute to ischemic injury [10]. In their
studies, neutropenia induced by antineutrophil serum amelio-
rated post-renal ischemic proximal tubule leakage [10]. In
contrast, Paller [11] and Thornton et al [12] were unable to
demonstrate a protective effect of PMN depletion on the course
of ischemic ARF. The reasons for the different conclusions of
the studies by Linas [9], Hellberg and Kallskog [10], and Paller
[11], and Thornton [12] are unknown but might relate to subtle
differences in the state of activation of PMN and/or the degree
of renal ischemia.
A number of circulating factors can heighten PMN respon-
siveness. These factors include LPS, PMA, platelet activating
factor, tumor necrosis factor, granulocyte-macrophage colony
stimulating factor and interleukin 1 [25]. Enhanced cellular
responses include locomotion, adhesiveness and secretion
functions such as oxidant and protease release [14, 15, 261.
PMN priming appears to be a general property since primed
PMN appear to respond nonselectively to a number of second-
ary stimuli [25]. The mechanism of priming is unknown but may
require alterations in cytoplasmic calcium content [27].
Most studies of primed PMN have been done in vitro. Our
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study provides additional insight into factors which activate
primed PMN and, for the first time, the actions of primed PMN
in a biological system. In addition to circulating factors, it
appears that ischemic (but not non-ischemic) kidneys activate
primed PMN. While the mechanism by which ischemic kidneys
activate primed PMN is not apparent from our studies, a
number of mechanisms are possible. PMN could be activated
by release of soluble factors from injured cells including chemo-
tactic phospholipids or products of cyclo-oxygenase or lipo-
oxygenase metabolism [28]. Alternatively, surface related alter-
ations in endothelial cell structure or function such as in
endothelial-leukocyte adhesion molecule [29] could account for
PMN activation.
Since PMN can be primed by a number of factors in addition
to LPS, we questioned whether ischemic kidney interaction
with primed PMN was specified for LPS priming or a more
generalized consequence of renal ischemia. Figure 4 demon-
strates that ischemic kidneys also appeared to activate PMN
primed with phorbol esters. Thus, it would appear that ischemic
kidney activation of primed PMN is a generalized phenomenon
independent of the priming agent.
When PMN are activated by circulating factors, a number of
different mediators can be released. The specific mediator
released is dependent on the PMN agonist. For example, PMA
is a relatively good stimulator of 02 metabolite release com-
pared to its effect on proteinase release [30]. By comparison,
LPS is a potent stimulus for proteinase as well as 02 metabolite
generation [16, 30]. In our study it appeared that when PMA-
primed kidneys were activated by ischemic kidneys, 02 metab-
olites were of primary importance in kidney injury since the
hydrogen peroxide scavenger CAT was protective. In contrast,
when LPS-primed PMN were activated by ischemic kidneys,
neutrophil elastase appeared to be a primary mediator of renal
injury since Eglin C was protective. However, the results
clearly demonstrate that with either PMA or LPS as priming
agents, both 02 metabolites and neutrophil elastase contribute
to renal injury since complete reversal of both LPS- and
PMA-primed PMN-induced injury could only be accomplished
in either situation when kidneys were perfused with both CAT
and Eglin C. Thus, in contrast to the relative specificity of
soluble PMN activators on mediator release, when primed
PMN's are activated by ischemic kidneys, release of PMN
mediators is not selective but involves both 02 metabolites and
elastase.
In earlier studies we demonstrated that oxygen metabolites
and elastase rather than either PMN effector alone mediated
renal injury when PMN were activated with LPS and formyl
peptides [8]. The new data expands on these studies and
suggests that ischemic kidney-mediated PMN activation also
results in both oxygen metabolite and elastase release rather
than to selective release of individual mediators.
After primed PMN are activated to release oxidants and
proteases there are a number of sites at which oxygen metab-
olites and elastase interact to enhance kidney injury. These
include oxidant-mediated activation of latent metalloprotein-
ases [221, inactivation of circulating antiproteinases such as a1
proteinase inhibitor and a2 macroglobulin [31, 32]. Alterna-
tively, oxygen metabolites could injure renal tissue, thereby
exposing sites susceptible to elastolytic attack.
Our current studies could explain the clinical observations
that mild renal ischemia (as occurs in prerenal azotemia)
predisposes the kidney to ARF. While mild renal ischemia
alone rarely results in ARF, mild ischemia in the setting of
nephrotoxins (for example, antibiotics, rhabdomyolysis) or
diseases associated with PMN priming (gram negative sepsis,
Adult Respiratory Distress Syndrome, multiple organ failure) is
frequently associated with ARF. Our results suggest the possi-
bility that in the setting of primed PMN, mild ischemia predis-
poses to ARF by activating primed PMN to release oxygen
metabolites and elastase.
Figure 8 summarizes the interaction between increasingly
activated PMN and isolated perfused kidneys subjected to
increasing degrees of ischemia. When kidneys are not ischemic,
neither inactive or primed PMN cause renal injury. In contrast,
kidneys which are underperfused for prolonged periods (for
example, 20 mm) are able to activate resting (as well as primed)
PMN to further worsen kidney injury. The new information
presented in this study suggests that kidneys experiencing mild
renal ischemia are more susceptible to injury from primed (but
not unstimulated) PMN and that the injury involves enhanced
sensitivity to both 02 metabolites and elastase. Finally, two
important caveats of our studies should be recognized: (1)
While the results of our studies clearly indicated that mild
ischemia and primed PMN interact to worsen isolated kidney
functions, it is possible that the results reflect additive rather
than synergistic effects of these two insults. (2) Although we
have shown that inactive [22], primed (this manuscript) and
activated [8, 22] PMN can contribute to ARF in vitro, a
definitive role of PMN in the pathogenesis of ARF in vivo
remains to be established.
PMN (functional state)
lschemia
(time) Untreated Primed
0mm 0 0
10mm 0
20 mm
Activated
'Jr
Fig. 8. Interaction between PMN and
+ isolated perfused kidneys. I Decrease in
GFR and TNa. —* No effect on GFR or
TNa.
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